Michael Cohen Dallas Elder Lawyer |

04 Jul Two copies of gene found to be underlying cause in Alzheimer’s Disease – are you Destiny’s Child?

Posted at 11:17h in Alzheimer’s, Asset Protection, Beneficiary, Dementia, End of Life Care Planning, Estate Planning, Guardianship, Long Term Care, Medicaid Application, Medicaid Planning, Michael Cohen Dallas Elder Lawyer, Nursing Home, Power of Attorney, Probate Administration, Public Benefits Protection

Researchers have found that people with 2 copies of the APOE4 gene is more than a risk factor – it is now considered an underlying cause of Alzheimer’s Disease. Prior to the research’s finding published in May, scientists knew the gene APOE4 increased risk. Although...

29 Sep Donanemab – The Next New Drug Likely To Be Approved In Slowing Memory Decline

Posted at 11:17h in Alzheimer’s, Estate Planning, Medicaid Application, Medicaid Planning, Michael Cohen Dallas Elder Lawyer, Probate Administration, Quality of Life

Earlier this year, leqembi (a drug that slows memory decline for those in the early stages of Alzheimer’s Disease by targeting the amyloid protein, usually common with those inflicted with Alzheimer’s as it begins to form) was approved by both FDA and CMS (governmental assistance...

26 Jul FDA Grants Approval for Drug that Slows Memory Loss

Posted at 13:33h in Alzheimer’s, Dementia, End of Life Care Planning, Estate Planning, Medicaid Application, Medicaid Planning, Medicare, Michael Cohen Dallas Elder Lawyer, Probate Administration

A milestone event in the fight against Alzheimer’s Disease occurred on July 6 when the FDA gave approval for a drug (Leqembi) that not only slows memory loss for those with Alzheimer’s Disease, but it was granted funding approval by the Centers for Medicare &...

17 Jun ALZHEIMER’S DRUG APPROVAL BRINGS HOPE

Posted at 16:25h in Alzheimer’s, Dementia, Estate Planning, Medicaid Planning, Medicare, Michael Cohen Dallas Elder Lawyer, Probate Administration

The FDA has recently approved the medication Aducanumab (which is to be given by infusion every four weeks) that studies have shown to slow the decline of cognitive and functional ability of patients (particularly if in the early stages after a diagnosis or those with...

06 Aug LARGE GRANT GIVEN TO DETERMINE IF LIFESTYLE INTERVENTION REDUCES ALZHEIMER’S RISK

Posted at 15:00h in Alzheimer’s, Dementia

The U.S. National Institute of Aging (NIA) is giving the University of California, Berkley a five year grant expected to total $47 million to determine whether lifestyle changes will reduce the risk of developing Alzheimer’s disease. The study will be used to determine if lifestyle interventions...